Doxorubicin and Vinorelbine Combination Chemotherapy

The combination of doxorubicin and vinorelbine is a chemotherapy regimen used primarily for treating advanced breast cancer. This combination leverages the complementary mechanisms of action of both drugs to target cancer cells effectively. Doxorubicin is an anthracycline antibiotic that works by intercalating with DNA and generating reactive oxygen species, ultimately leading to DNA damage and cell death. Vinorelbine is a vinca alkaloid that acts as an anti-mitotic agent, disrupting microtubule formation during cell division. When combined, these drugs demonstrate significant activity against breast cancer, with reported overall response rates of 50-57%, median time to progression of approximately 10 months, and median overall survival of about 25 months. The standard regimen typically involves doxorubicin 50 mg/m² on day 1 and vinorelbine 25 mg/m² on days 1 and 8, administered in 21-day cycles. An alternative regimen using pegylated liposomal doxorubicin (35 mg/m²) with vinorelbine (25 mg/m² on days 1 and 8) administered in 3-week intervals has also been studied, showing similar efficacy with potentially reduced cardiotoxicity. The most common adverse effects include granulocytopenia (grade 4: 83%, grade 3: 12%), febrile neutropenia requiring hospitalization (8%), stomatitis (grade 4: 5%), alopecia (grade 3: 15%), and nausea/vomiting (grade 3: 12%). Cardiotoxicity is a rare but serious concern with doxorubicin. The pegylated liposomal formulation shows a somewhat different toxicity profile, with palmar-plantar erythrodysesthesia syndrome and mucositis being more prominent, but with reduced cardiotoxicity. This regimen is generally well-tolerated and has shown excellent patient acceptance.